About FDA

Division of Oncology Products 1 (DOP1)

The Division of Oncology Products 1 (DOP1) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for breast, gynecologic, and genitourinary cancers, as well as supportive care (non-hematologic) products.

Management Team

Director: Julia A. Beaver, MD
Deputy Director: Amna Ibrahim, MD
Deputy Director for Safety: Katherine Fedenko, MS, CRNP
Associate Director of Labeling: William Pierce, PharmD
Chief Project Management Staff: Christy Cottrell
Chief Project Management Staff: Alice Kacuba, RN, MSN
Project Specialist: Dolores Bowen'

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Oncology Products 1 (DOP1)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Phone: (301) 796-2330
Fax: (301) 796-9845


Page Last Updated: 01/31/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English